Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy participants (Parts A and B) and participants with T2DM diagnosed at least 1 year before enrollment (Part C)~* Have a screening body mass index (BMI) of greater than 18.5 and less than or equal to 40.0 kilograms per meter squared (kg/m²), inclusive~* Participants with T2DM (Part C only): have T2DM controlled with diet and exercise alone or are stable on a single oral antidiabetic medication (metformin for at least 30 days or sulfonylureas). Participants receiving sulfonylureas may participate only if this treatment is stopped for at least 6 weeks before dosing with study drug~Exclusion Criteria:~* Have known allergies to tirzepatide, glucagon-like peptide (GLP)-1 analogs, or related compounds~* Have an abnormality in the 12-lead electrocardiogram (ECG) at screening that, in the opinion of the investigator, increases the risks associated with participating in the study~* Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase (greater than 2-fold the upper limit of normal \[ULN\]) or gastrointestinal (GI) disorder (for example, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (for example, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase (DPP)-IV inhibitors~Participants with T2DM (Part C only)~* Have had more than 1 episode of severe hypoglycemia, as defined by the American Diabetes Association criteria, within 6 months before entry into the study or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms~All Study Participants (Parts B and C only)~* have known allergies to tirzepatide, GLP-1 analogs, or related compounds, or acetaminophen

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Tirzepatide (Part A) (Type: EXPERIMENTAL): Participants received escalating single doses of either 0.25 milligram (mg) or 0.5mg or 1mg, or 2.5mg or 5mg or 8mg Tirzepatide by subcutaneous injection.
- Placebo (Part A) (Type: PLACEBO_COMPARATOR): Participants received single dose of placebo by subcutaneous injection.
- Tirzepatide (Part B) (Type: EXPERIMENTAL): Participants received fixed doses of either 0.5mg or 1.5mg or 4.5mg Tirzepatide once weekly for four weeks or titrated doses of 5mg, 5mg, 8mg and 10mg Tirzepatide once weekly for four weeks by subcutaneous injection.
- Placebo (Part B) (Type: PLACEBO_COMPARATOR): Participants received placebo once weekly for four weeks by subcutaneous injection.
- Dulaglutide (Part B) (Type: ACTIVE_COMPARATOR): Participants received 1.5mg Dulaglutide once weekly for four weeks by subcutaneous injection.
- Tirzepatide (Part C) (Type: EXPERIMENTAL): Participants received fixed doses of either 0.5mg or 5mg Tirzepatide once weekly for four weeks or titrated doses of 5mg,5mg,10mg,10mg or 5mg,5mg,10mg,15mg Tirzepatide once weekly for four weeks by subcutaneous injection
- Placebo (Part C) (Type: PLACEBO_COMPARATOR): Participants received placebo once weekly for four weeks by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).